Prevention and treatment of FGFR inhibitor-associated toxicities

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Fibroblast growth factor receptor (FGFR) inhibitors demonstrate efficacy in malignancies with FGFR genetic aberrations.
• These targeted therapies represent a personalized medicine approach for rare cancers like cholangiocarcinoma.
• While generally well-tolerated, FGFR inhibitors present unique toxicities distinct from other tyrosine kinase inhibitors.

Purpose of the Study:

• To review and summarize the unique toxicities associated with FGFR inhibitors.
• To provide an emphasis on the management strategies for these specific adverse events.
• To support sustained patient treatment by addressing treatment-limiting toxicities.

Main Methods:

• Literature review of clinical trials and published studies on FGFR inhibitors.
• Analysis of reported adverse events and toxicities.
• Synthesis of information regarding the management of unique FGFR inhibitor-associated toxicities.

Main Results:

• FGFR inhibitors are associated with distinct toxicities that can necessitate dose adjustments or treatment cessation.
• Effective management protocols are essential to mitigate these adverse events.
• Understanding and addressing these toxicities can improve patient adherence and treatment continuity.

Conclusions:

• Managing unique FGFR inhibitor toxicities is key to optimizing therapeutic benefits.
• Further research into proactive management strategies is warranted.
• This review aims to guide clinicians in the effective care of patients receiving FGFR inhibitors.